{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for sulfisoxazole root_references_citation in Reference Text / Citation (approximate match)
Status:
US Previously Marketed
Source:
KYNEX ACETYL PEDIATRIC by LEDERLE
(1961)
Source URL:
First approved in 1958
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
US Previously Marketed
Source:
SULFISOXAZOLE by HEATHER
(1982)
Source URL:
First approved in 1948
Source:
GANTRISIN by ROCHE
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Sulfisoxazole is a sulfonamide antibacterial antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfisoxazole acetyl in combination with erythromycin ethylsuccinate is used for treatment of ACUTE OTITIS MEDIA in children that is caused by susceptible strains of Haemophilus influenzae. Sulfisoxazole acetyl is a prodrug of sulfisoxazole. Acetyl group is added to make the drug poorly water soluble, and is hydrolyzed in vivo to the active drug. Sulfisoxazole and its acetylated metabolites are excreted primarily by the kidneys through glomerular filtration. Sulfisoxazole is a competitive inhibitor of the enzyme dihydropteroate synthetase. It inhibits bacterial synthesis of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid
Status:
Possibly Marketed Outside US
Source:
The Zoeun Skin Nourishing Cream by Sturgeonbio Co.,Ltd
(2023)
Source URL:
First approved in 2023
Source:
The Zoeun Skin Nourishing Cream by Sturgeonbio Co.,Ltd
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
NCT04677712: Phase 4 Interventional Completed Edematous Fibrosclerotic Panniculopathy (EFP)
(2020)
Source URL:
First approved in 2022
Source:
M020
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
Mostal Lashes and Brows Enhancing Serum by Pella Pharmaceuticals Co. Ltd
(2020)
Source URL:
First approved in 2020
Source:
Mostal Lashes and Brows Enhancing Serum by Pella Pharmaceuticals Co. Ltd
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2020)
Source URL:
First approved in 2020
Source:
505G(a)(3)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Possibly Marketed Outside US
Source:
BOTANIC TWENTY HYPERCARE PLUMPING FORMULA by RITZY NOBLE CO., LTD.
(2018)
Source URL:
First approved in 2018
Source:
BOTANIC TWENTY HYPERCARE PLUMPING FORMULA by RITZY NOBLE CO., LTD.
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
Derma Firm Eye by Pella Pharmaceuticals Co. Ltd
(2020)
Source URL:
First approved in 2018
Source:
21 CFR 334
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
VITA VOLU 101 ESSENCE by B&P COSMETIC, INC.
(2017)
Source URL:
First approved in 2017
Source:
VITA VOLU 101 ESSENCE by B&P COSMETIC, INC.
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
OcluVet NAC Nutritional Lubricant Eye Drops by AMBIENCE FAMILY INC
(2024)
Source URL:
First approved in 2017
Source:
21 CFR 346
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
